Shots:

• The US FDA has approved Trijardy XR which includes Jardiance (empagliflozin)- Tradjenta (linagliptin) and metformin hydrochloride extended-release to lower blood sugar in adults with T2D- along with diet and exercise
• The approval is based on Trijardy XR assessing the bioequivalence of Trijardy XR and their individual components in healthy adults- demonstrating a consistent safety profile of the therapy with their individual components
• Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended-release tablets) is a prescription therapy- available in 4 different dosages to lower the blood sugar level in patients with T2D with CV disease

Click here ­to­ read full press release/ article 

Ref: Eli Lilly | Image: Eli Lilly